Discovery and optimization of pyrazoline derivatives as promising monoamine oxidase inhibitors

Current Topics in Medicinal Chemistry

Volumn 12, Issue 20, 2012, Pages 2240-2257

  Secci, Daniela ^a   Carradori, Simone ^a   Bolasco, Adriana ^a   Bizzarri, Bruna ^a   D'Ascenzio, Melissa ^a   Maccioni, Elias ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Alzheimer's disease; Antidepressant agents; Isocarboxazid; Monoamine oxidase; Parkinson's disease; Pyrazoline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ISOCARBOXAZID; MONOAMINE OXIDASE INHIBITOR; PYRAZOLINE DERIVATIVE;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG SYNTHESIS; HUMAN; MOLECULAR DOCKING; NONHUMAN; PROCESS OPTIMIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84874905503     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612805220057     Document Type: Article

References (70)

1. Strolin-Benedetti, M.; Tipton, K.F.; Whomsley, R. Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?. Fundam. Clin. Pharmacol., 2007, 21, 1472-8206.
2. Shih, J.C.; Chen, K.; Ridd, M. Monoamine oxidase: from genes to behavior. J. Annu. Rev. Neurosci., 1999, 22, 197-217.
3. Kalgutkar, A.S.; Dalvie, D.K.; Castagnoli, N. Jr.; Taylor, T.J. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol., 2001, 14, 1139-1162.
4. Cesura, A.M.; Pletscher, A. The new generation of monoamine oxidase inhibitors. Prog. Drug Res., 1992, 38, 171-297.
5. Saura, J.; Luque, J.M.; Cesura, A.M.; Da Prada, M.; Chan-Palay, V.; Huber, G.; Loffler, J.; Richards, J.G. Increased monoamine oxidase B activity in plaque associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience, 1994, 62, 15-30.
6. Amrein, R.; Martin, J.R.; Cameron, A.M. Moclobemide in patients with dementia and depression. Adv. Neurol., 1999, 80, 509-519.
7. Binda, C.; Aldeco, M.; Geldenhuys, W. J.; Tortorici, M.; Mattevi, A.; Edmondson, D. E. Molecular insights into human monoamine oxidase B inhibition by the glitazone antidiabetes drugs. ACS Med. Chem. Lett. 2012, 3, 39-42.
8. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmonson, D.E.; Mattevi, A. Three-dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 12684-12689.
9. Bolasco, A.; Fioravanti, R.; Carradori, S. Recent development of monoamine oxidase inhibitors. Expert Opin. Ther. Patents, 2005, 15, 1763-1782.
10. Bolasco, A.; Carradori, S.; Fioravanti, R. Focusing on new monoamine oxidase inhibitors. Expert Opin. Ther. Patents, 2010, 20, 909-939.
11. Carradori, S.; Secci, D.; Bolasco, A.; Chimenti, P.; D'Ascenzio, M. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential. Expert Opin. Ther. Patents, 2012, 22, 759-801.
12. Wouters, J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr. Med. Chem., 1998, 5, 137-162.
13. Reyes-Parada, M.; Fierro, A.; Iturriaga-Vásquez, P.; Cassels, B.K. Monoamine oxidase inhibition in the light of new structural data. Curr. Enzyme Inhib., 2005, 1, 85-95.
14. Kalgutkar, A.S.; Dalvie, D.K., Castagnoli, N. Jr.; Taylor, T.J. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol., 2001, 14, 1139-1162.
15. López-Muñoz, F.; Alamo, C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr. Pharm. Des., 2009, 15, 1559-1562.
16. Parmar, S.S.; Pandey, B.R.; Dwivedi, C.; Harbison, R.D. Anticonvulsant activity and monoamine oxidase inhibitory properties of 1,3,5-trisubstituted pyrazolines. J. Pharm. Sci., 1974, 63, 1152-1155;
17. Soni, N.; Pande, K.; Kalsi, R.; Kupta, K.T.; Parmar, S.S.; Barthwal, J. P. Inhibition of rat brain monoamine oxidase and succinic dehydrogenase by anticonvulsant pyrazolines. Res. Commun. Chem. Pathol. Pharmacol, 1987, 56, 129-132.
18. Kumar, S.; Bawa, S.; Drabu, S.; Kumar, R.; Gupta, H. Biological activities of pyrazoline derivatives: A recent development. Recent Patents on Anti-Infect. Drug Discov., 2009, 4, 154-163.
19. Shaaban, M.R.; Mayhoub, A.S.; Farag, A.M. Recent advances in the therapeutic applications of pyrazolines Expert Opin. Ther. Patents, 2012, 22, 253-291.
20. Porsolt, R.D.; LePichon, M.; Jaifre, M. Depression: A new animal model sensitive to antidepressant treatments. Nature, 1977, 266, 730-732.
21. Tanaka, M.; Telegdy, G. Involvement of adrenergic and serotonergic receptors in antidepressant-like effect of urocortin 3 in a modified forced swimming test in mice. Brain Res. Bull, 2008, 77, 301-305.
22. Taha, A.M.; Omar, N.M.; Bayomi, S.M.; Ammar, E.M.; Afifi, A. Synthesis and screening of cyclic benzylhydrazine congeners as antidepressants. J. Pharm. Sci., 1974, 63, 395-398.
23. Maryanoff, B.E.; McComsey, D.F.; Costanzo, M.J.; Setler, P.E.; Gardocki, J.F.; Shank, R.P.; Schneider, C.R. Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin. J. Med. Chem., 1984, 27, 946-947.
24. Pellow, S.; Chopin, P.; File, S.E.; Briley, M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods, 1985, 14, 149-167.
25. Cryan, J.F.; Markou, A.; Lucki, I. Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol. Sci., 2002, 23, 238-245.
26. Griebel, G.; Perrault, G.; Sanger, D.J. Behavioral profiles of the reversible monoamine-oxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology, 1997, 131, 180-186.
27. Krueger, M.J.; Mazouz, F.; Ramsay, R.R.; Milcent, R.; Singer, T.P. Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors. Biochem. Biophys. Res. Commun., 1995, 206, 556-562.
28. Hubálek, F.; Binda, C; Khalil, A.; Li, M.; Mattevi, A.; Castagnoli, N.; Edmonson, D.E. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase. J. Biol. Chem., 2005, 280, 15761-15766.
29. Novaroli, L.; Daina, A.; Favre, E.; Bravo, J.; Carotti, A.; Legnetti, F.; Catto, M.; Carrupt, P.A.; Reist, M. Impact of species-dependent differences on screening, design, and development of MAO B inhibitors. J. Med. Chem., 2006, 49, 6264-6272.
30. Wiley, R.H.; Behr, L.C.; Fusco, R; Jarboe, C.H. The Chemistry of Heterocyclic Compounds: Pyrazoles, Pyrazolines, Pyrazolidines, Indazoles and Condensed Rings; John Wiley & Sons, Ltd: New York, 1967.
31. Elguero, J. In: Comprehensive Heterocyclic Chemistry; Pergamon: Oxford, 1996.
32. Gökhan, N.; Yeşilada, A.; Uçar, G.; Erol, K.; Bilgin, A.A. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and evaluation as MAO inhibitors. Arch. Pharm. Pharm. Med. Chem., 2003, 336, 362-371.
33. Secci, D.; Bolasco, A.; Chimenti, P.; Carradori, S. The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents. Curr. Med. Chem., 2011, 18, 5114-5144
34. Millard, C.B.; Broomfield, C.A. Anticholinesterases: medical applications of neurochemical principles, J. Neurochem., 1995, 64, 1909-1918.
35. Chopra, K.; Misra, S.; Kuhad, A. Current perspectives on pharmacotherapy of Alzheimer's disease. Expert Opin. Pharmacother., 2011, 12, 335-350.
36. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Cirilli, R.; La Torre, F.; Alcaro, S.; Ortuso, F.; Langer, T. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1 H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors. Curr. Med. Chem., 2006, 13, 1411-1428.
37. Manna, F.; Chimenti, F.; Bolasco, A.; Bizzarri, B.; Befani, O.; Pietrangeli, P.; Mondovi, B.; Turini, P. Inhibitory effect of 1,3,5-triphenyl-4,5-dihydro-(1 H)-pyrazole derivatives on activity of amine oxidases. J. Enzyme Inhib., 1998, 13, 207-216.
38. Manna, F.; Chimenti, F.; Bolasco, A.; Bizzarri, B.; Befani, O.; Turini, P.; Giovannini, V.; Mondovi, B. Selective inhibition of FAD and copper-dependent amine oxidases by N-acetyl pyrazole derivatives. Inflamm. Res., 2001, 50, 128-129.
39. Manna, F.; Chimenti, F.; Bolasco, A.; Secci, D.; Bizzarri, B.; Befani, O.; Turini, P.; Mondovi, B.; Alcaro, S.; Tafi, A. Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1 H)-pyrazole derivatives. Bioorg. Med. Chem. Lett., 2002, 12, 3629-3633.
40. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Befani, O.; Turini, P.; Giovannini, V.; Mondovi, B.; Cirilli, R.; La Torre, F. Synthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1 H)-pyrazole derivatives against monoamine oxidase. J. Med. Chem., 2004, 47, 2071-2074.
41. Cirilli, R.; Ferretti, R.; Gallinella, B.; Turchetto, L.; Bolasco, A.; Secci, D.; Chimenti, P.; Pierini, M.; Fares, V.; Befani, O.; La Torre, F. Enantiomers of C5-chiral 1-acetyl-3,5-diphenyl-4,5-dihydro-(1 H)-pyrazole derivatives: analytical and semipreparative HPLC separation, chiroptical properties, absolute configuration, and inhibitory activity against monoamine oxidase. Chirality, 2004, 16, 625-636.
42. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F. Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1 H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors. Chem. Biol. Drug Des., 2006, 67, 206-214.
43. Harkcom, W.T.; Bevan, D.R. Molecular docking of inhibitors into monoamine oxidase B. Biochem. Biophys. Res. Commun., 2007, 360, 401-406.
44. Chimenti, F.; Fioravanti, R.; Bolasco, A.; Manna, F.; Chimenti, P.; Secci, D.; Rossi, F.; Turini, P.; Ortuso, F.; Alcaro, S.; Cardia, M.C. Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1 H)-pyrazole derivatives. Eur. J. Med. Chem., 2008, 43, 2262-2267.
45. Chimenti, F.; Maccioni, E.; Secci, D.; Bolasco, A.; Chimenti, P.; Granese, A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F.; Cirilli, R.; La Torre, F.; Cardia, M.C; Distinto, S. Synthesis, molecular modeling studies, and selective inhibitory activity against monoamine oxidase of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1 H)-pyrazole derivatives. J. Med. Chem., 2005, 48, 7113-7122.
46. Cirilli, R.; Simonelli, A.; Ferretti, R.; Bolasco, A.; Chimenti, P.; Secci, D.; Maccioni, E.; La Torre, F. Analytical and semipreparative high performance liquid chromatography enantioseparation of new substituted 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1 H)-pyrazoles on polysaccharide-based chiral stationary phases in normal-phase, polar organic and reversed-phase conditions. J. Chromatogr. A, 2006, 1101, 198-203.
47. Chimenti, F.; Carradori, S.; Secci, D.; Bolasco, A.; Bizzarri, B.; Chimenti, P.; Granese, A.; Yáñez, M.; Orallo, F. Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1 H)-pyrazole derivatives. Eur. J. Med. Chem., 2010, 45, 800-804.
48. Yáñez, M.; Fraiz, N.; Cano, E.; Orallo, F. Inhibitory effects of cis- and trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on monoamine oxidase activity. Biochem. Biophys. Res. Commun., 2006, 344, 688-695.
49. Palaska, E.; Aydin, F.; Uçar, G.; Erol, D. Synthesis and monoamine oxidase inhibitory activities of 1-thiocarbamoyl-3,5-diphenyl-4,5-dihydro-1 H-pyrazole derivatives. Arch. Pharm. Chem. Life Sci., 2008, 341, 209-215.
50. Fioravanti, R; Bolasco, A.; Manna, F.; Rossi, F.; Orallo, F.; Yáñez, M.; Vitali, A.; Ortuso, F.; Alcaro, S. Synthesis and molecular modelling studies of prenylated pyrazolines as MAO-B inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 6479-6482.
51. Oldfield, E. Targeting isoprenoid biosynthesis for drug discovery: Bench to bedside. Acc. Chem. Res., 2010, 43, 1216-1226.
52. Uçar, G.; Gökhan, N.; Yeşilada, A.; Bilgin, A.A. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: A novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci. Lett., 2005, 382, 327-331.
53. Decker, M. Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. Mini-Rev. Med. Chem., 2007, 7, 221-229.
54. Gökhan-Kelekçi, N.; Yabanoglu, S.; Küpeli, E.; Salgin, U.; Özgen, Ö.; Uçar, G.; Yeşilada, E.; Kendi, E.; Yeşilada, A.; Bilgin, A.A. A new therapeutic approach in Alzheimer disease: Some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg. Med. Chem., 2007, 15, 5775-5786.
55. Bekhit, A.A.; Hymete, A.; Bekhit, E.-D.A.A.; Damtew, A.; Aboul-Enein, Y.H. Pyrazoles as promising scaffold for the synthesis of anti-inflammatory and/or antimicrobial agent: A review. Mini-Rev. Med. Chem., 2010, 10, 1014-1033.
56. Şentürk, K.; Tan, O.U.; Çiftçi, S.Y.; Uçar, G.; Palaska, E. Synthesis and evaluation of human monoamine oxidase inhibitory activities of some 3,5-diaryl-N-substituted-4,5-dihydro-1 H-pyrazole-1-carbothioamide derivatives. Arch. Pharm. Chem. Life Sci. 2012, 345, 695-702.
57. Maccioni, E.; Alcaro, S.; Orallo, F.; Cardia, M.C; Distinto, S.; Costa, G.; Yáñez, M.; Sanna, M.L.; Vigo, S.; Meleddu, R.; Secci, D. Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase. Eur. J. Med. Chem., 2010, 45, 4490-4498.
58. Jayaprakash, V.; Sinha, B.N.; Uçar, G.; Ercan, A. Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 6362-6368.
59. Jayaprakash, V.; Yabanoglu, S.; Sinha, B.N.; Uçar, G. Pyrazoline-based mycobactin analogues as dual inhibitors of MAO/cholinesterase. Turk. J. Biochem., 2010, 35, 91-98.
60. Ellman, G.L.; Courtney, K.D.; Andres, Jr V.; Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol, 1961, 7, 88-95.
61. Karuppasamy, M.; Mahapatra, M.; Yabanoglu, S.; Uçar, G.; Sinha, B.N.; Basu, A.; Mishra, N.; Sharon, A; Kulandaivelu, U.; Jayaprakash, V. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem., 2010, 18, 1875-1881.
62. Holt, A.; Sharman, D.F.; Baker, G.B.; Pelcic, M.M. Continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal. Biochem., 1997, 244, 384-392.
63. Sahoo, A.; Yabanoglu, S.; Sinha, B.N.; Uçar, G.; Basu, A.; Jayaprakash, V. Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies. Bioorg. Med. Chem. Lett., 2010, 20, 132-136.
64. Tripathi, S.; Pandey, B.R.; Barthwal, J.P.; Kishor, K.; Bhargava, K.P. Novel indolylpyrazolines as monoamine oxidase inhibitors. Indian J. Physiol. Pharmacol, 1980, 24, 155-159.
65. Gökhan-Kelekçi, N.; Koyunoglu, S.; Yabanoglu, S.; Yelekçi, K.; Ozgen, O.; Uçar, G.; Erol, K.; Kendi, E.; Yeşilada, A. New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: Synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. Bioorg. Med. Chem., 2009, 17, 675-689.
66. Mishra, N.; Sasmal, D. Development of selective and reversible pyrazoline based MAO-B inhibitors: Virtual screening, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2011, 21, 1969-1973.
67. Mishra, N.; Sasmal, D. Anthracene pyrazoline derivatives as inhibitors of monoamine oxidase A and B. IN2010KO01146, July 15, 2011.
68. Mishra, N.; Sasmal, D. Modulations of brain amines and dopaminergic behavior by a novel, reversible and selective MAO-B inhibitor. Brain Res., 2012, 1470, 45-51.
69. Helicon Therapeutics, Inc. Preparation of substituted pyrazoles as MAO-B inhibitors. US2007203154, August 30, 2007.
70. Matsumoto, T.; Suzuki, O.; Furuta, T.; Asai, M.; Kurokawa, Y.; Nimura, Y.; Katsumata, Y.; Takahashi, I. A sensitive fluorometric assay for serum monoamine oxidase with kynuramine as substrate. Clin. Biochem., 1985, 18, 126-129.